Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer

Autor: Johan Isaksson, Christina Karlsson, Bianca Stenmark, Jessica Carlsson, Alvida Qvick, Gisela Helenius
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Male
0301 basic medicine
Lung Neoplasms
Disease
medicine.disease_cause
Gastroenterology
Biochemistry
Circulating Tumor DNA
0302 clinical medicine
Cytology
Stage (cooking)
Predictive testing
Early Detection of Cancer
Genetics (clinical)
Aged
80 and over
Middle Aged
Prognosis
030220 oncology & carcinogenesis
Molecular Medicine
Female
KRAS
Cell-Free Nucleic Acids
Research Article
Adult
medicine.medical_specialty
RM1-950
QD415-436
03 medical and health sciences
Internal medicine
Biomarkers
Tumor
Genetics
medicine
Humans
Liquid biopsy
Lung cancer
Molecular Biology
Aged
Neoplasm Staging
Cancer och onkologi
business.industry
Liquid Biopsy
Reproducibility of Results
medicine.disease
Survival Analysis
Molecular medicine
030104 developmental biology
Cancer and Oncology
Mutation
Therapeutics. Pharmacology
Neoplasm Grading
business
Zdroj: Molecular Medicine, Vol 27, Iss 1, Pp 1-14 (2021)
Molecular Medicine
ISSN: 1528-3658
1076-1551
Popis: Background The aim of this study was to investigate the clinical value of liquid biopsy as a primary source for variant analysis in lung cancer. In addition, we sought to characterize liquid biopsy variants and to correlate mutational load to clinical data. Methods Circulating cell-free DNA was extracted from plasma from patients with lung cancer (n = 60) and controls with benign lung disease (n = 16). Variant analysis was performed using the AVENIO ctDNA Surveillance kit and the results were correlated to clinical and variant analysis data from tumor tissue or cytology retrieved from clinical routine diagnostics. Results There were significantly more variants detected in lung cancer cases compared to controls (p = 0.011), but no difference between the histological subgroups of lung cancer was found (p = 0.465). Furthermore, significantly more variants were detected in patients with stage IIIb–IV disease compared to patients with stage I–IIIa (median 7 vs 4, p = 0.017). Plasma cfDNA mutational load was significantly associated with overall survival (p = 0.010). The association persisted when adjusted for stage and ECOG performance status (HR: 3.64, 95% CI 1.37–9.67, p = 0.009). Agreement between tumor and plasma samples significantly differed with stage; patients with stage IIIb–IV disease showed agreement in 88.2% of the cases with clinically relevant variants, compared to zero cases in stage I–IIIa (p = 0.004). Furthermore, one variant in EGFR, two in KRAS, and one in BRAF were detected in plasma but not in tumor samples. Conclusion This study concludes that in the vast majority of advanced NSCLC patients a reliable variant analysis can be performed using liquid biopsy from plasma. Furthermore, we found that the number of variants in plasma is associated with prognosis, possibly indicating a strategy for closer follow up on this crucial patient group.
Databáze: OpenAIRE
Externí odkaz: